We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Visit expo >

Gold Member

Clinical Chemistry Assay

Sorbitol Dehydrogenase (SDH)

Online QC Software
Acusera 24•7

Electrolyte Analyzer

BKE-B

Repetitive Pipette

VWR® Stepper Pro

Latest MEDICA 2022 News

Channels

Clinical Chemistry

view channel

Image: New urine test provides a simple way to screen for autism in children (Photo courtesy of Andy DeLisle/ASU Knowledge Enterprise)

Urine-Based Test Shows Promise for Autism Screening in Children

Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more

Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation

The TOBY Test for Alzheimer’s Disease from TOBY, Inc. (Austin, TX, USA) has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation as an aid in the diagnosis of Alzheimer’s disease.... Read more

Molecular Diagnostics

view channel

Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection

Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read more

PATHFINDER 2 Study: Screen Detected Cancers (Photo courtesy of GRAIL)

Multi-Cancer Test Boosts Detection When Added to Standard Screening

Most cancers are still diagnosed outside organ-specific screening, often at advanced stages. In the United States, guideline-recommended screening detects only 14% of cancers, underscoring the need for... Read more

Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia

In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), molecular blood testing for minimal residual disease (MRD) can detect signs of impending relapse before clinical symptoms emerge.... Read more

Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer

Metastatic prostate cancer remains a major treatment challenge, particularly when deciding whether to add chemotherapy to hormonal therapy. In the United States, about 334,000 men are diagnosed with prostate... Read more

Hematology

view channel

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more

Image: Direct and indirect antitumoral effects of eosinophil (Marie Gilon et al., Journal of Experimental & Clinical Cancer Research (2026). DOI: 10.1186/s13046-026-03688-5)

Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children

Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Immunology

view channel

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more

Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more

Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring

Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more

Microbiology

view channel

Image: Graphical Abstract (Microbiome Research Reports: DOI:10.20517/mrr.2025.96)

Gut Microbiome Signatures Help Identify Risk of IBD Progression

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more

FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets

Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more

New AMR Assay Supports Rapid Infection Control Screening in Hospitals

As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more

Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo

In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more

Pathology

view channel

AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes

Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more

Image: Graphical Abstract (Eldad D. Shulman et al., AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology, Cell (2026). DOI: 10.1016/j.cell.2026.04.023)

Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images

Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more

AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification

Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read more

Technology

view channel

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Agentic AI Platform Supports Genomic Decision-Making in Oncology

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more

Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more

Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read more

Industry

view channel

Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean

Alzheimer’s disease assessment remains challenging in many regions where aging populations are increasing demand for care, but access to dementia specialists and advanced imaging remains limited.... Read more

Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand

Multiplex assays enable simultaneous detection and measurement of multiple analytes in a single sample, supporting faster analysis across diagnostics, biomarker discovery, drug development, and life sciences... Read more

Global Framework Integrates Digital Pathology for Companion Diagnostic Development

Leica Biosystems (Nussloch, Germany) and CellCarta (Montreal, QC, Canada) have expanded a coordinated companion diagnostic (CDx) development model to biopharma sponsors worldwide. Built on operational... Read more

GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026

GRAIL (Menlo Park, CA, USA) reported detailed clinical utility, performance, and safety findings from its landmark NHS-Galleri trial during an oral presentation on May 30 at the 2026 American Society of... Read more